新型聚合物偶联人IL-15增强CD19靶向CAR T细胞免疫治疗疗效
靶向CD19的CAR T细胞治疗复发/难治B细胞恶性肿瘤部分患者不能获得持久缓解,输注后低血清IL-15与CAR T细胞动力学不佳相关。NKTR-255是一种聚合物偶联IL-15,在非人灵长类增强T细胞和NK细胞增殖,体外促进人CD19 CAR T细胞增殖,荷淋巴瘤免疫缺陷小鼠中增强抗肿瘤疗效且CAR T细胞计数持续升高。
要点
- CAR T输注后低血清IL-15与CAR T细胞动力学不佳相关
- NKTR-255在非人灵长类增强T细胞和自然杀伤细胞增殖
- NKTR-255联合CD19 CAR T在荷瘤小鼠中增强抗肿瘤疗效
核心结论
- NKTR-255联合CD19 CAR T细胞可增强抗肿瘤疗效,支持正在进行的复发/难治B细胞恶性肿瘤联合治疗1期临床试验。
研究设计与样本
- 非人灵长类药代动力学和免疫细胞药效学研究、体外研究及荷淋巴瘤免疫缺陷小鼠体内研究。
- 引用一项针对B细胞恶性肿瘤的CD19 CAR T细胞1/2期临床试验(#NCT01865617)的观察结果。
主要发现
- 在CD19 CAR T细胞治疗B细胞恶性肿瘤的1/2期临床试验(#NCT01865617)中,CAR T细胞输注后低血清IL-15浓度与较差的CAR T细胞动力学相关。
- NKTR-255在非人灵长类中增强T细胞和自然杀伤细胞的体内增殖。
- 体外NKTR-255诱导人CD19 CAR T细胞剂量依赖性增殖和积累,尤其在靶细胞丰度低时。
- 荷淋巴瘤免疫缺陷小鼠中,与单用CAR T细胞相比,接受CAR T细胞联合NKTR-255的小鼠血液和骨髓中CAR T细胞计数显著更高,且在肿瘤清除后持续存在,Ki-67和抑制性受体共表达评估未见持续增殖或持续活化/耗竭证据。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR)-modified T-cell therapies targeting CD19 represent a new treatment option for patients with relapsed/refractory (R/R) B-cell malignancies. However, CAR T-cell therapy fails to elicit durable responses in a significant fraction of patients. Limited in vivo proliferation and survival of infused CAR T cells are key causes of failure. In a phase 1/2 clinical trial of CD19 CAR T cells for B-cell malignancies (#NCT01865617), low serum interleukin 15 (IL-15) concentration after CAR T-cell infusion was associated with inferior CAR T-cell kinetics. IL-15 supports T-cell proliferation and survival, and therefore, supplementation with IL-15 may enhance CAR T-cell therapy. However, the clinical use of native IL-15 is challenging because of its unfavorable pharmacokinetic (PK) and toxicity. NKTR-255 is a polymer-conjugated IL-15 that engages the entire IL-15 receptor complex (IL-15Rα/IL-2Rβγ) and exhibits reduced clearance, providing sustained pharmacodynamic (PD) responses. We investigated the PK and immune cell PDs in nonhuman primates treated with NKTR-255 and found that NKTR-255 enhanced the in vivo proliferation of T cells and natural killer cells. In vitro, NKTR-255 induced dose-dependent proliferation and accumulation of human CD19 CAR T cells, especially at low target cell abundance. In vivo studies in lymphoma-bearing immunodeficient mice demonstrated enhanced antitumor efficacy of human CD19 CAR T cells. In contrast to mice treated with CAR T cells alone, those that received CAR T cells and NKTR-255 had markedly higher CAR T-cell counts in the blood and marrow that were sustained after tumor clearance, without evidence of persistent proliferation or ongoing activation/exhaustion as assessed by Ki-67 and inhibitory receptor coexpression. These data support an ongoing phase 1 clinical trial of combined therapy with CD19 CAR T cells and NKTR-255 for R/R B-cell malignancies.
引用
- Hirayama AV, Chou CK, Miyazaki T, et al. A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy. Blood Adv. 2023. PMID: 36332004. doi:10.1182/bloodadvances.2022008697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。